PaTHway Phase 3 Trial Analysis
Hypoparathyroidism Disease Etiology and Medical History
Characteristics
TransCon PTH
(N = 61)
Placebo
(N = 21)
Cause of Hypoparathyroidism (HP)
Acquired from neck surgery
52 (85.2)
18 (85.7)
Autoimmune disease
1 (1.6)
0
Intrinsic genetic defects of the parathyroid glands
3 (4.9)
0
Idiopathic disease
4 (6.6)
3 (14.3)
Other
1 (1.6)
0
Duration of HP (Years) (n)
61
21
12.0
11.1
1,56
1,33
Mean
Min, Max
Patient History
Renal Insufficiency History
Kidney Stones History
Ectopic Calcifications History
Vascular Calcifications History
Brain Calcification History
Cataract History
Seizure History
12
Data on file, Ascendis Pharma 2022.
5 (8.2)
1 (4.8)
15 (24.6)
4 (19.0)
0
0
1 (1.6)
1 (1.6)
3 (4.9)
0
0
0
1 (4.8)
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
Pathway
TRIAL
ascendis
pharmaView entire presentation